Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1286
Peer-review started: July 29, 2021
First decision: October 25, 2021
Revised: November 3, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: February 6, 2022
Primary Sjögren's syndrome (pSS) concomitant with autoimmune hemolytic anemia (AIHA) but without eye and mouth dryness is exceedingly rare. Iguratimod (IGU) has been widely used in the treatment of pSS. However, there are few reports about the application of IGU in pSS concomitant with AIHA.
Here, we present the case of a patient with pSS concomitant with AIHA but without eye and mouth dryness. The patient was initially diagnosed with hyperplastic anemia and AIHA while pSS was missed, and was finally diagnosed with pSS concomitant with AIHA. The patient was treated with IGU along with prednisone and hydroxychloroquine, and her hemoglobin, reticulocytes and IgG returned to normal levels.
IGU was effective for and well tolerated by our patient with pSS concomitant with AIHA, and may be a promising therapy for the treatment of this disease.
Core Tip: Primary Sjögren's syndrome (pSS) concomitant with autoimmune hemolytic anemia (AIHA) but without eye and mouth dryness is exceedingly rare. Iguratimod (IGU) has been widely used in the treatment of pSS. However, there are few reports about the application of IGU in pSS concomitant with AIHA. Here, we present the case of a patient with pSS concomitant with AIHA who was successfully treated with IGU. IGU was effective for and well tolerated by our patient with pSS concomitant with AIHA, and may be a promising therapy for treatment of this disease.